The End of Days for H5N1 Moratorium?

Experts in Washington have reached an agreement over how to fund avian influenza research.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, THEGREENJAfter a 2-day meeting in Bethesda, Maryland, this week, government officials have finally reached a consensus on a policy to review requests to research the potentially dangerous H5N1 influenza virus. The new policy could end a longstanding debate that began when two research groups published studies showing their ability to create viruses that are transmissible between mammals. The National Institutes of Health policy, which is to take effect next month, will effectively lift a 12-month ban on H5N1 research that started in January. But some countries may not wait. “I suspect that we will be seeing a lifting of the moratorium on the part of people who are not NIH-funded,” Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases (NIAID), said at the meeting, according to ScienceInsider.

The new policy is designed to help reviewers decide which “gain-of-function” experiments to fund. Research on H5N1 makes up less than 10 percent of NIAID’s total influenza research spending budget, with gain-of-function experiments making up only 1 percent of the total influenza budget, which should expedite review.

Such studies were at the crux of the moratorium because they provided the possibility of engineering new mutations into the virus that could make it more easily transmissible or more virulent. However, many researchers have stated that these types of experiments are crucial for understanding how the virus might naturally mutate into a more dangerous, pandemic-causing strains, and thus such research could help prevent natural outbreaks, or help to more quickly develop a vaccine. The risk, however, is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies